Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up)

Treatment of moderate-to-severe AD with UPA15 or UPA30, with dose escalation or dose reduction based on achievement of the optimal treatment target of EASI 90 at week 12, demonstrated that both approaches support the achievement and maintenance of EASI 90 at week 24. Overall safety findings were consistent with the known UPA safety profile, with no new safety signals identified.

Authors

Institutions

Publication Details

Journal
British Journal of Dermatology
Published
2025-06-21
DOI
https://doi.org/10.1093/bjd/ljaf236
Citations
4
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
8.02
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up)

Dedee Frances Murrell, Kave Shams, Gweneth Levy, Marius Rademaker et al.
4 citations
British Journal of Dermatology
Dermatology and Skin Diseases
8.02
article

Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up)

Dedee Frances Murrell, Kave Shams, Gweneth Levy, Marius Rademaker, Wan‐Ju Annabelle Lee, Shinichi Imafuku, Witold Owczarek, Athanasios Tsianakas, Vimal H. Prajapati, Alvaro Moreira, Yu Han, Nadia Ibrahim, Melinda Gooderham, Tiago Torres
article en
4 citations

Abstract

Treatment of moderate-to-severe AD with UPA15 or UPA30, with dose escalation or dose reduction based on achievement of the optimal treatment target of EASI 90 at week 12, demonstrated that both approaches support the achievement and maintenance of EASI 90 at week 24. Overall safety findings were consistent with the known UPA safety profile, with no new safety signals identified.

British Journal of DermatologyVol. 193(6)
National Academy of Medicine (US), The University of Sydney (AU), University of Leeds (GB), University of Calgary (CA), Queen's University (CA), Chapel Allerton Hospital (GB), Waikato Hospital (NZ), AbbVie (United States) (US), UNSW Sydney (AU), Fukuoka University (JP), SKiN Health (CA), Calgary Laboratory Services (CA), Zentralklinik Bad Berka (DE), NIHR Leeds Musculoskeletal Biomedical Research Unit (GB), Wojskowy Instytut Medycyny Lotniczej (PL), Probity Medical Research (CA), Clinical Trials New Zealand (NZ), Centro Hospitalar do Porto (PT), Skin Health Institute (AU)
Good health and well-being
Openalex Percentile: Top 3%
Dermatology and Skin Diseases
8.02
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.